| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
PPARs: therapeutic targets for metabolic disease.
|
Trends Pharmacol Sci
|
2005
|
2.90
|
|
2
|
Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor.
|
Bioorg Med Chem Lett
|
2002
|
2.21
|
|
3
|
Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
|
Bioorg Med Chem Lett
|
2008
|
1.62
|
|
4
|
Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump.
|
J Biol Chem
|
2003
|
1.33
|
|
5
|
Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity.
|
J Biol Chem
|
2002
|
1.14
|
|
6
|
Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity.
|
ChemMedChem
|
2013
|
1.13
|
|
7
|
A series of novel, potent, and selective histone deacetylase inhibitors.
|
Bioorg Med Chem Lett
|
2006
|
1.10
|
|
8
|
Ivermectin and nodulisporic acid receptors in Drosophila melanogaster contain both gamma-aminobutyric acid-gated Rdl and glutamate-gated GluCl alpha chloride channel subunits.
|
Biochemistry
|
2002
|
0.99
|
|
9
|
Discovery of a pharmacologically active antagonist of the two-pore-domain potassium channel K2P9.1 (TASK-3).
|
ChemMedChem
|
2011
|
0.90
|
|
10
|
PPAR ligands: potential therapies for metabolic syndrome.
|
Curr Diab Rep
|
2005
|
0.90
|
|
11
|
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
|
J Med Chem
|
2005
|
0.87
|
|
12
|
Selective PPARgamma modulators with improved pharmacological profiles.
|
Bioorg Med Chem Lett
|
2005
|
0.85
|
|
13
|
The differential interactions of peroxisome proliferator-activated receptor gamma ligands with Tyr473 is a physical basis for their unique biological activities.
|
Mol Pharmacol
|
2007
|
0.84
|
|
14
|
A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
|
Eur J Pharmacol
|
2008
|
0.84
|
|
15
|
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.
|
J Med Chem
|
2009
|
0.83
|
|
16
|
A disubstituted succinamide is a potent sodium channel blocker with efficacy in a rat pain model.
|
Biochemistry
|
2004
|
0.82
|
|
17
|
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
|
J Med Chem
|
2011
|
0.82
|
|
18
|
Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs.
|
Bioorg Med Chem Lett
|
2012
|
0.80
|
|
19
|
Design of potent and selective GPR119 agonists for type II diabetes.
|
Bioorg Med Chem Lett
|
2010
|
0.79
|
|
20
|
Novel transcriptome profiling analyses demonstrate that selective peroxisome proliferator-activated receptor γ (PPARγ) modulators display attenuated and selective gene regulatory activity in comparison with PPARγ full agonists.
|
Mol Pharmacol
|
2012
|
0.79
|
|
21
|
Nocathiacin analogs: Synthesis and antibacterial activity of novel water-soluble amides.
|
Bioorg Med Chem Lett
|
2009
|
0.79
|
|
22
|
Recent advances in the modulation of voltage-gated ion channels for the treatment of epilepsy.
|
Curr Drug Targets CNS Neurol Disord
|
2002
|
0.77
|
|
23
|
Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.
|
Bioorg Med Chem Lett
|
2005
|
0.77
|
|
24
|
Highly functionalized 7-azaindoles as selective PPAR gamma modulators.
|
Bioorg Med Chem Lett
|
2008
|
0.76
|
|
25
|
Design and synthesis of potent and subtype-selective PPARalpha agonists.
|
Bioorg Med Chem Lett
|
2005
|
0.75
|
|
26
|
Novel cyclopentane dicarboxamide sodium channel blockers as a potential treatment for chronic pain.
|
Bioorg Med Chem Lett
|
2005
|
0.75
|
|
27
|
Conversion of nocathiacin I to nocathiacin acid by a mild and selective cleavage of dehydroalanine.
|
J Org Chem
|
2007
|
0.75
|
|
28
|
Discovery of potent and use-dependent sodium channel blockers for treatment of chronic pain.
|
Bioorg Med Chem Lett
|
2005
|
0.75
|
|
29
|
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
|
J Med Chem
|
2009
|
0.75
|
|
30
|
Synthesis of side chain truncated 3"-aldehyde, 3"-carboxylic acid, and 1"-aldehyde from nodulisporic acid A.
|
Org Lett
|
2002
|
0.75
|
|
31
|
Side-chain homologation of nodulisporic acid: synthesis of potent new dienyl derivatives.
|
Bioorg Med Chem Lett
|
2002
|
0.75
|
|
32
|
Nodulisporic acid side-chain modifications: access to the 2", 3", 4", and 6" registers.
|
Bioorg Med Chem Lett
|
2003
|
0.75
|
|
33
|
Design, synthesis, structure-function relationship, bioconversion, and pharmacokinetic evaluation of ertapenem prodrugs.
|
J Med Chem
|
2014
|
0.75
|